| Business Summary | | Allergan,
Inc.
is
a
provider
of
eye
care
and
specialty
pharmaceutical
products
throughout
the
world
with
products
in
the
eye
care
pharmaceutical,
ophthalmic
surgical
device,
over-the-counter
contact
lens
care,
movement
disorder
and
dermatological
markets.
The
Company's
worldwide
consolidated
revenues
are
principally
generated
by
prescription
and
non-prescription
pharmaceutical
products
in
the
areas
of
ophthalmology
and
skin
care,
neurotoxins,
intraocular
lenses
and
other
ophthalmic
surgical
products
and
contact
lens
care
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Allergan,
Inc.
is
a
provider
of
eye
care
and
specialty
pharmaceutical
products
throughout
the
world
with
products
in
the
eye
care
pharmaceutical,
ophthalmic
surgical
device,
over-the-counter
contact
lens,
movement
disorder
and
dermatological
markets.
For
the
six
months
ended
6/29/01,
net
sales
rose
6%
to
$854.8
million.
Net
income
before
acct.
change
fell
21%
to
$75.8
million.
Results
reflect
increased
U.S.
Eye
Care
Pharmaceutical
sales,
offset
by
an
increase
in
R&D
cost. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Pyott, 47 Chairman,
Pres, CEO | $1.5M | $6.3M | Eric Brandt, 38 CFO,
VP, Pres - Global Consumer Eye Care Bus. | 581K | 3.1M | James Hindman, 40 Sr.
VP, Controller | -- | -- | Jacqueline Schiavo, 52 Corp.
VP, Worldwide Operations | -- | -- | Lester Kaplan, Ph.D., 50 Corp.
VP; Pres, R&D and Global BOTOX | 605K | 12.7M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|